These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. CRISPR/Cas gene editing in the human germline. Bekaert B; Boel A; Cosemans G; De Witte L; Menten B; Heindryckx B Semin Cell Dev Biol; 2022 Nov; 131():93-107. PubMed ID: 35305903 [TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9-mediated genome editing in nonhuman primates. Kang Y; Chu C; Wang F; Niu Y Dis Model Mech; 2019 Oct; 12(10):. PubMed ID: 31636095 [TBL] [Abstract][Full Text] [Related]
9. Mosaicism in CRISPR/Cas9-mediated genome editing. Mehravar M; Shirazi A; Nazari M; Banan M Dev Biol; 2019 Jan; 445(2):156-162. PubMed ID: 30359560 [TBL] [Abstract][Full Text] [Related]
10. Making sense of heritable human genome editing: Scientific and ethical considerations. Greenfield A Prog Mol Biol Transl Sci; 2021; 182():1-28. PubMed ID: 34175039 [TBL] [Abstract][Full Text] [Related]
11. Design and Validation of CRISPR/Cas9 Systems for Targeted Gene Modification in Induced Pluripotent Stem Cells. Lee CM; Zhu H; Davis TH; Deshmukh H; Bao G Methods Mol Biol; 2017; 1498():3-21. PubMed ID: 27709565 [TBL] [Abstract][Full Text] [Related]
12. [Research progress in the third-generation genomic editing technology - CRISPR/Cas9]. Zhou Y; Zong Y; Kong X Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2016 Oct; 33(5):713-6. PubMed ID: 27577230 [TBL] [Abstract][Full Text] [Related]
13. National Academies relax stance on germline edits. Sheridan C Nat Biotechnol; 2017 Apr; 35(4):295-296. PubMed ID: 28398320 [No Abstract] [Full Text] [Related]
14. CRISPR-Cas immunity, DNA repair and genome stability. Cubbon A; Ivancic-Bace I; Bolt EL Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30209206 [TBL] [Abstract][Full Text] [Related]
15. Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment. Jiang C; Meng L; Yang B; Luo X Clin Genet; 2020 Jan; 97(1):73-88. PubMed ID: 31231788 [TBL] [Abstract][Full Text] [Related]
16. Baculoviral delivery of CRISPR/Cas9 facilitates efficient genome editing in human cells. Hindriksen S; Bramer AJ; Truong MA; Vromans MJM; Post JB; Verlaan-Klink I; Snippert HJ; Lens SMA; Hadders MA PLoS One; 2017; 12(6):e0179514. PubMed ID: 28640891 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of mutation rates, mosaicism and off target mutations when injecting Cas9 mRNA or protein for genome editing of bovine embryos. Hennig SL; Owen JR; Lin JC; Young AE; Ross PJ; Van Eenennaam AL; Murray JD Sci Rep; 2020 Dec; 10(1):22309. PubMed ID: 33339870 [TBL] [Abstract][Full Text] [Related]
18. Challenges in Gene Therapy for Somatic Reverted Mosaicism in X-Linked Combined Immunodeficiency by CRISPR/Cas9 and Prime Editing. Hou Y; Ureña-Bailén G; Mohammadian Gol T; Gratz PG; Gratz HP; Roig-Merino A; Antony JS; Lamsfus-Calle A; Daniel-Moreno A; Handgretinger R; Mezger M Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553615 [TBL] [Abstract][Full Text] [Related]
19. From the first human gene-editing to the birth of three-parent baby. Zhang X; Wang S Sci China Life Sci; 2016 Dec; 59(12):1341-1342. PubMed ID: 27904999 [No Abstract] [Full Text] [Related]
20. Human dignity and gene editing: Using human dignity as an argument against modifying the human genome and germline is a logical fallacy. de Miguel Beriain I EMBO Rep; 2018 Oct; 19(10):. PubMed ID: 30237156 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]